Pernille Lindsø Andersen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pernille Lindsø Andersen has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Gregor Borut Ernst Jemec
Department of Dermatology and Allergy, PHOENIX Research Center Copenhagen University Hospital ‐ Herlev and Gentofte Gentofte Denmark
14 shared publications - Ditte Marie Lindhardt Saunte
Department of Clinical Medicine, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
11 shared publications - Ole Birger Pedersen
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
6 shared publications - Christian Erikstrup
Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
4 shared publications - Jonas Olsen
Department of Dermatology, Zealand University Hospital, Roskilde, Denmark
3 shared publications - Khoa Manh Dinh
Department of Clinical Immunology Aarhus University Hospital Aarhus Denmark
3 shared publications
Latest Publications
- Open Access
- 11 September 2025
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2559004
It is still a secret disease – clinical images in randomized controlled trials on hidradenitis suppurativa
Hidradenitis suppurativa (HS) is a recalcitrant, chronic, inflammatory skin disease characterized by painful nodules, abscesses, and tunnels, primarily affecting intertriginous areas. Despite its substantial negative impact on patients' quality of life, HS has been historically understudied. Recently, an increasing number of randomized controlled trials (RCTs) have expanded treatment options and informed clinical guidelines. While quantitative data using clinical scoring systems is standard to disseminate RCT results, this study aimed to assess the extent of clinical image dissemination, as this can increase transparency and support layperson communication. A systematic review was performed on 265 identified articles, of which 37 met the inclusion criteria. Each trial was evaluated for the inclusion of clinical images and the number of patients represented. Clinical images were included in 15 of 37 trials (40.5%), depicting only 33 of 4,327 randomized patients (0.7%) across 90 photos. Articles published before 2020 more frequently included photos than those published later (p = 0.008). The low inclusion rate of clinical photos in HS RCTs is, however, slightly higher than in comparable psoriasis and atopic dermatitis studies. Given dermatology's visual nature, the limited use of clinical photos in HS RCTs is notable. Increasing clinical photo dissemination in scientific articles may enhance research transparency, aid young physicians' education, and improve patient communication. However, standardized photo protocols and ethical considerations are essential for implementation.
- 11 September 2025
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2559004
Open AccessIt is still a secret disease – clinical images in randomized controlled trials on hidradenitis suppurativa
Hidradenitis suppurativa (HS) is a recalcitrant, chronic, inflammatory skin disease characterized by painful nodules, abscesses, and tunnels, primarily affecting intertriginous areas. Despite its substantial negative impact on patients' quality of life, HS has been historically understudied. Recently, an increasing number of randomized controlled trials (RCTs) have expanded treatment options and informed clinical guidelines. While quantitative data using clinical scoring systems is standard to disseminate RCT results, this study aimed to assess the extent of clinical image dissemination, as this can increase transparency and support layperson communication. A systematic review was performed on 265 identified articles, of which 37 met the inclusion criteria. Each trial was evaluated for the inclusion of clinical images and the number of patients represented. Clinical images were included in 15 of 37 trials (40.5%), depicting only 33 of 4,327 randomized patients (0.7%) across 90 photos. Articles published before 2020 more frequently included photos than those published later (p = 0.008). The low inclusion rate of clinical photos in HS RCTs is, however, slightly higher than in comparable psoriasis and atopic dermatitis studies. Given dermatology's visual nature, the limited use of clinical photos in HS RCTs is notable. Increasing clinical photo dissemination in scientific articles may enhance research transparency, aid young physicians' education, and improve patient communication. However, standardized photo protocols and ethical considerations are essential for implementation.
- Open Access
- 18 August 2025
- Published by Danish Medical Association in Ugeskrift for Læger
- Vol. 187 (34) , 1-2
Myeloidt sarkom som led i akut myeloid leukæmi
- 18 August 2025
- Published by Danish Medical Association in Ugeskrift for Læger
- Vol. 187 (34) , 1-2
Open AccessMyeloidt sarkom som led i akut myeloid leukæmi
- Open Access
- 7 July 2025
- Published by S. Karger AG in Dermatology
- Vol. 241 (Suppl. 1) , 87-91
Prevalence of Hidradenitis Suppurativa in Oman
Introduction: This study, conducted as part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative, aimed to ascertain the prevalence of hidradenitis suppurativa (HS) in Oman and to assess its demographic distribution, adhering to standardized methodology for consistency across participating sites. Methods: A multicenter approach was undertaken, encompassing primary care within a general practice clinic, along with two secondary surgical clinics at Sumail Hospital and Seeb polyclinic in Oman. Informed written and oral consent were diligently obtained from study participants. Data collection involved the translation of the questionnaire into Arabic and meticulous examination conducted by qualified physicians. Recruitment transpired from July 2022 to September 2022, targeting healthy adults accompanying patients, with rigorous adherence to predefined exclusion criteria. Results: Among the 500 initially selected participants, 484 questionnaires were subjected to rigorous analysis, following the exclusion of 16 due to data incompleteness. The estimated prevalence of HS in Oman was found to be 2.1% (95% CI: 1.1–3.8%), with a pronounced predilection toward the female demographic. Notably, the median age of participants with HS was significantly lower than that of their healthy counterparts. Regional distribution analysis revealed the axillary region as the most commonly affected site for both genders. The questionnaire-based diagnostic approach exhibited a sensitivity of 1.00 and a specificity of 0.73, indicating its efficacy in HS diagnosis. Conclusion: This study yields critical insights into the epidemiology of HS in Oman, conclusively establishing a prevalence rate of 2.1%. The high sensitivity and specificity of the questionnaire-based diagnostic tool emphasize its clinical utility. These findings collectively emphasize the imperative for comprehensive education and awareness campaigns among healthcare professionals to foster early detection and tailored intervention strategies. To further enrich our understanding of HS pathophysiology and optimize patient management, larger prospective investigations are warranted.
- 7 July 2025
- Published by S. Karger AG in Dermatology
- Vol. 241 (Suppl. 1) , 87-91
Open AccessPrevalence of Hidradenitis Suppurativa in Oman
Introduction: This study, conducted as part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative, aimed to ascertain the prevalence of hidradenitis suppurativa (HS) in Oman and to assess its demographic distribution, adhering to standardized methodology for consistency across participating sites. Methods: A multicenter approach was undertaken, encompassing primary care within a general practice clinic, along with two secondary surgical clinics at Sumail Hospital and Seeb polyclinic in Oman. Informed written and oral consent were diligently obtained from study participants. Data collection involved the translation of the questionnaire into Arabic and meticulous examination conducted by qualified physicians. Recruitment transpired from July 2022 to September 2022, targeting healthy adults accompanying patients, with rigorous adherence to predefined exclusion criteria. Results: Among the 500 initially selected participants, 484 questionnaires were subjected to rigorous analysis, following the exclusion of 16 due to data incompleteness. The estimated prevalence of HS in Oman was found to be 2.1% (95% CI: 1.1–3.8%), with a pronounced predilection toward the female demographic. Notably, the median age of participants with HS was significantly lower than that of their healthy counterparts. Regional distribution analysis revealed the axillary region as the most commonly affected site for both genders. The questionnaire-based diagnostic approach exhibited a sensitivity of 1.00 and a specificity of 0.73, indicating its efficacy in HS diagnosis. Conclusion: This study yields critical insights into the epidemiology of HS in Oman, conclusively establishing a prevalence rate of 2.1%. The high sensitivity and specificity of the questionnaire-based diagnostic tool emphasize its clinical utility. These findings collectively emphasize the imperative for comprehensive education and awareness campaigns among healthcare professionals to foster early detection and tailored intervention strategies. To further enrich our understanding of HS pathophysiology and optimize patient management, larger prospective investigations are warranted.
- 30 June 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (4) , 786-788
Methylene blue photodynamic therapy of antifungal-unresponsive (resistant) dermatophytosis
This study was an exploratory, single-centre, open-label, uncontrolled investigation of methylene blue photodynamic therapy (MB-PDT) for the treatment of antifungal-resistant dermatophytosis. One-third of participants with antifungal-resistant dermatophytosis responded to two sessions of MB-PDT therapy. The small sample size and limited number of treatment sessions were possibly insufficient to investigate the true potential of this approach.
- 30 June 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (4) , 786-788
Methylene blue photodynamic therapy of antifungal-unresponsive (resistant) dermatophytosis
This study was an exploratory, single-centre, open-label, uncontrolled investigation of methylene blue photodynamic therapy (MB-PDT) for the treatment of antifungal-resistant dermatophytosis. One-third of participants with antifungal-resistant dermatophytosis responded to two sessions of MB-PDT therapy. The small sample size and limited number of treatment sessions were possibly insufficient to investigate the true potential of this approach.
- 3 March 2023
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (7) , 1989-1994
Symptoms of attention deficit hyperactivity disorder are associated with Hidradenitis suppurativa in Danish blood donors
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with psychiatric comorbidity. Attention deficit hyperactivity disorder (ADHD) is a mental disorder associated with systemic and skin inflammation such as psoriasis and atopic dermatitis. Whether HS symptoms are associated with ADHD symptoms remains unexplored. Thus, the aim of this study was to explore the possible association between HS and ADHD. Participants in the Danish Blood Donor Study (DBDS) were included in this cross-sectional study during 2015–2017. The participants provided questionnaire data on screening items of HS, ADHD symptoms (ASRS-score), and depressive symptoms, smoking and body mass index (BMI). A logistic regression with HS symptoms as a binary outcome predicted by ADHD adjusted for age, sex, smoking, BMI, and depression was conducted to investigate the association between HS and ADHD. A total of 52,909 Danish blood donors were included in the study. Of these were 1004/52,909 (1.9%) considered participants with HS. Of the participants with HS, 74/996 (7.4%) screened positive of ADHD symptoms, while only 1786/51,129 (3.5%) of the participants without HS screened positive of ADHD. Adjusted for confounders, ADHD was positively associated with HS, odds ratio 1.85 (95% confidence interval: 1.43–2.37). Psychiatric comorbidity of HS is not limited to depression and anxiety. This study shows a positive association between HS and ADHD. Further research on the biological mechanisms behind this association is warranted.
- 3 March 2023
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (7) , 1989-1994
Symptoms of attention deficit hyperactivity disorder are associated with Hidradenitis suppurativa in Danish blood donors
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with psychiatric comorbidity. Attention deficit hyperactivity disorder (ADHD) is a mental disorder associated with systemic and skin inflammation such as psoriasis and atopic dermatitis. Whether HS symptoms are associated with ADHD symptoms remains unexplored. Thus, the aim of this study was to explore the possible association between HS and ADHD. Participants in the Danish Blood Donor Study (DBDS) were included in this cross-sectional study during 2015–2017. The participants provided questionnaire data on screening items of HS, ADHD symptoms (ASRS-score), and depressive symptoms, smoking and body mass index (BMI). A logistic regression with HS symptoms as a binary outcome predicted by ADHD adjusted for age, sex, smoking, BMI, and depression was conducted to investigate the association between HS and ADHD. A total of 52,909 Danish blood donors were included in the study. Of these were 1004/52,909 (1.9%) considered participants with HS. Of the participants with HS, 74/996 (7.4%) screened positive of ADHD symptoms, while only 1786/51,129 (3.5%) of the participants without HS screened positive of ADHD. Adjusted for confounders, ADHD was positively associated with HS, odds ratio 1.85 (95% confidence interval: 1.43–2.37). Psychiatric comorbidity of HS is not limited to depression and anxiety. This study shows a positive association between HS and ADHD. Further research on the biological mechanisms behind this association is warranted.
- 15 February 2023
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 9 (3) , 195-202
Two Novel Human Leukocyte Antigen Alleles Are Associated with Decreased Risk of Onychomycosis in a Large Cohort of Danish Blood Donors
Introduction: Antigen presentation and antimicrobial immune responses involve the human leukocyte antigen (HLA) system. Onychomycosis is primarily caused by dermatophytes and affects around 5.5% of the population worldwide. Yet, only limited data exist on the associations between the HLA system and onychomycosis. Thus, the objective of the study was to investigate if there is an association between HLA alleles and onychomycosis. Methods: Participants in the Danish Blood Donor Study were defined as cases of onychomycosis and controls based on antifungal prescriptions in the national prescription registry. Associations were investigated using logistic regressions adjusted for confounders and were Bonferroni corrected for multiple tests. Results: A total of 3,665 participants were considered onychomycosis cases, and 24,144 participants were considered controls. We found two protective HLA alleles of onychomycosis: DQB1*06:04, odds ratios (OR) 0.80 (95% confidence interval (CI) 0.71–0.90), and DRB1*13:02, OR 0.79 (95% CI: 0.71–0.89). Conclusion: The finding of two novel protective alleles of onychomycosis indicates that certain HLA alleles have certain antigen presentation properties affecting the risk of fungal infection. These findings may provide the basis for future research identifying immunologically relevant antigens of fungi causing onychomycosis, which could ultimately lead to targets of new drugs with antifungal effects.
- 15 February 2023
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 9 (3) , 195-202
Two Novel Human Leukocyte Antigen Alleles Are Associated with Decreased Risk of Onychomycosis in a Large Cohort of Danish Blood Donors
Introduction: Antigen presentation and antimicrobial immune responses involve the human leukocyte antigen (HLA) system. Onychomycosis is primarily caused by dermatophytes and affects around 5.5% of the population worldwide. Yet, only limited data exist on the associations between the HLA system and onychomycosis. Thus, the objective of the study was to investigate if there is an association between HLA alleles and onychomycosis. Methods: Participants in the Danish Blood Donor Study were defined as cases of onychomycosis and controls based on antifungal prescriptions in the national prescription registry. Associations were investigated using logistic regressions adjusted for confounders and were Bonferroni corrected for multiple tests. Results: A total of 3,665 participants were considered onychomycosis cases, and 24,144 participants were considered controls. We found two protective HLA alleles of onychomycosis: DQB1*06:04, odds ratios (OR) 0.80 (95% confidence interval (CI) 0.71–0.90), and DRB1*13:02, OR 0.79 (95% CI: 0.71–0.89). Conclusion: The finding of two novel protective alleles of onychomycosis indicates that certain HLA alleles have certain antigen presentation properties affecting the risk of fungal infection. These findings may provide the basis for future research identifying immunologically relevant antigens of fungi causing onychomycosis, which could ultimately lead to targets of new drugs with antifungal effects.
- Open Access
- 24 December 2022
- Published by MDPI AG in Journal of Fungi
- Vol. 9 (1) , 33
An Increase in Specialist Treatment for Onychomycosis: An Unexplained Tendency. A Retrospective Study of Patients Treated for Onychomycosis in Danish Hospitals from 1994 to 2018
Onychomycosis is a common disease with a significant negative impact on quality of life. While the disease is usually manageable in general practice, a proportion of patients need specialist treatment in academic hospital clinics. However, it is an unknown question whether the incidence in those needing specialist treatments is changing. Furthermore, the comorbidity burden in this patient population severely affected by onychomycosis has never been characterized. We conducted a retrospective study on patients treated for onychomycosis in Danish hospitals from 1994 to 2018. The cohort was observed for 24 years, and the data comprise 7.2 million Danes and their hospital diagnoses. A disease trajectory algorithm was used to examine the comorbidity burden in the cohort. A total of 2,271 patients received hospital treatment for onychomycosis during the time period, of which 1358 (59.8%) were men. The data show an increase in the incidence of hospital-treated cases since 2012 and that the most common comorbidities in this patient population include cardiovascular disease, alcohol-related diagnoses, and diabetes. One explanation of the increase in specialist treatment may include a general increase in patients with decreased resilience to fungal disease. This lack of resilience may both include an increasing elderly population with atherosclerosis, diabetes, and immunosuppression but also a potential increase in patients treated with immunosuppressive agents. Another possible explanation may include a shift in patient expectations in the case of treatment failure. Thus, patients may have an increasing demand for specialist treatment. While our data document an increase in the number of patients in need of specialist treatment for onychomycosis, we suggest future research to examine the general incidence of onychomycosis but also whether this increase in an apparently recalcitrant disease may be attributed to increased antifungal resistance, more specialist treatment options, or increased attention to dermatomycoses.
- 24 December 2022
- Published by MDPI AG in Journal of Fungi
- Vol. 9 (1) , 33
Open AccessAn Increase in Specialist Treatment for Onychomycosis: An Unexplained Tendency. A Retrospective Study of Patients Treated for Onychomycosis in Danish Hospitals from 1994 to 2018
Onychomycosis is a common disease with a significant negative impact on quality of life. While the disease is usually manageable in general practice, a proportion of patients need specialist treatment in academic hospital clinics. However, it is an unknown question whether the incidence in those needing specialist treatments is changing. Furthermore, the comorbidity burden in this patient population severely affected by onychomycosis has never been characterized. We conducted a retrospective study on patients treated for onychomycosis in Danish hospitals from 1994 to 2018. The cohort was observed for 24 years, and the data comprise 7.2 million Danes and their hospital diagnoses. A disease trajectory algorithm was used to examine the comorbidity burden in the cohort. A total of 2,271 patients received hospital treatment for onychomycosis during the time period, of which 1358 (59.8%) were men. The data show an increase in the incidence of hospital-treated cases since 2012 and that the most common comorbidities in this patient population include cardiovascular disease, alcohol-related diagnoses, and diabetes. One explanation of the increase in specialist treatment may include a general increase in patients with decreased resilience to fungal disease. This lack of resilience may both include an increasing elderly population with atherosclerosis, diabetes, and immunosuppression but also a potential increase in patients treated with immunosuppressive agents. Another possible explanation may include a shift in patient expectations in the case of treatment failure. Thus, patients may have an increasing demand for specialist treatment. While our data document an increase in the number of patients in need of specialist treatment for onychomycosis, we suggest future research to examine the general incidence of onychomycosis but also whether this increase in an apparently recalcitrant disease may be attributed to increased antifungal resistance, more specialist treatment options, or increased attention to dermatomycoses.
- 17 November 2022
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (4) , 895-902
Human leukocyte antigen system associations in Malassezia-related skin diseases
Background The human leukocyte antigen system (HLA) is divided into two classes involved in antigen presentation: class I presenting intracellular antigens and class II presenting extracellular antigens. While susceptibility to infections is correlated with the HLA system, data on associations between HLA genotypes and Malassezia-related skin diseases (MRSD) are lacking. Thus, the objective of this study was to investigate associations between HLA alleles and MRSD. Materials and methods Participants in The Danish Blood Donor Study (2010–2018) provided questionnaire data on life style, anthropometric measures, and registry data on filled prescriptions. Genotyping was done using Illumina Infinium Global Screening Array, and HLA alleles were imputed using the HIBAG algorithm. Cases and controls were defined using filled prescriptions on topical ketoconazole 2% as a proxy of MRSD. Logistic regressions assessed associations between HLA alleles and MRSD adjusted for confounders and Bonferroni corrected for multiple tests. Results A total of 9455 participants were considered MRSD cases and 24,144 participants as controls. We identified four risk alleles B*57:01, OR 1.19 (95% CI: 1.09–1.31), C*01:02, OR 1.19 (95% CI: 1.08–1.32), C*06:02, OR 1.14 (95% CI: 1.08–1.22), and DRB1*01:01, OR 1.10 (95% CI: 1.04–1.17), and two protective alleles, DQB1*02:01, OR 0.89 (95% CI: 0.85–0.94), and DRB1*03:01, OR 0.89 (95% CI: 0.85–0.94). Conclusion Five novel associations between HLA alleles and MRSD were identified in our cohort, and one previous association was confirmed. Future studies should assess the correlation between Malassezia antigens and antigen-binding properties of the associated HLA alleles.
- 17 November 2022
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (4) , 895-902
Human leukocyte antigen system associations in Malassezia-related skin diseases
Background The human leukocyte antigen system (HLA) is divided into two classes involved in antigen presentation: class I presenting intracellular antigens and class II presenting extracellular antigens. While susceptibility to infections is correlated with the HLA system, data on associations between HLA genotypes and Malassezia-related skin diseases (MRSD) are lacking. Thus, the objective of this study was to investigate associations between HLA alleles and MRSD. Materials and methods Participants in The Danish Blood Donor Study (2010–2018) provided questionnaire data on life style, anthropometric measures, and registry data on filled prescriptions. Genotyping was done using Illumina Infinium Global Screening Array, and HLA alleles were imputed using the HIBAG algorithm. Cases and controls were defined using filled prescriptions on topical ketoconazole 2% as a proxy of MRSD. Logistic regressions assessed associations between HLA alleles and MRSD adjusted for confounders and Bonferroni corrected for multiple tests. Results A total of 9455 participants were considered MRSD cases and 24,144 participants as controls. We identified four risk alleles B*57:01, OR 1.19 (95% CI: 1.09–1.31), C*01:02, OR 1.19 (95% CI: 1.08–1.32), C*06:02, OR 1.14 (95% CI: 1.08–1.22), and DRB1*01:01, OR 1.10 (95% CI: 1.04–1.17), and two protective alleles, DQB1*02:01, OR 0.89 (95% CI: 0.85–0.94), and DRB1*03:01, OR 0.89 (95% CI: 0.85–0.94). Conclusion Five novel associations between HLA alleles and MRSD were identified in our cohort, and one previous association was confirmed. Future studies should assess the correlation between Malassezia antigens and antigen-binding properties of the associated HLA alleles.
- Open Access
- 12 December 2021
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 101 (12) , adv00617
Quality of Life in Danish Blood Donors Treated for Superficial Fungal Infections
Is missing (Short communication)
- 12 December 2021
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 101 (12) , adv00617
Open AccessQuality of Life in Danish Blood Donors Treated for Superficial Fungal Infections
Is missing (Short communication)